The effect of androgen deprivation on lipoprotein profile and cardiovascular risk in men with advanced prostatic carcinoma is a matter of controversy. We describe an experimental model to evaluate the effects of orchidectomy and oestrogen and luliberin analogue administration on lipoprotein profiles in male Sprague-Dawley rats. Eighty rats were divided into three treatment groups and a control group. Results were compared with the scanty human data found in the literature. The oestrogen group was that which showed more differences compared with the control group, but its lipoprotein profile differed from that obtained in humans. Orchidectomy and luliberin analogue groups showed fewer differences than the oestrogen group, but a non-favourable lipoprotein profile in terms of cardiovascular risk was observed. There were important differences between humans and rats with regard to lipoprotein profile, suggesting that rats are probably not a good model for the study of atherogenic risk.
Introduction
Androgen deprivation was introduced over 50 years ago by Huggins & Hodges (1) for the treatment of prostatic carcinoma. This effective mode of treatment is administered in almost all cases of prostatic cancer considered to be surgically incurable. Orchidectomy, oestrogens and luliberin analogues are effective tools for hormone treatment in advanced disease, and are used interchangeably according to patient or physician preferences since their clinical effects are similar in patients with hormone-sensitive prostatic cancer (2) . These three forms of androgen deprivation therapy act at different levels in the metabolic pathway of androgen synthesis and lipoprotein metabolism which change plasma lipoprotein profile. Nowadays, prostatic carcinoma is perhaps the most frequent cancer in men with an incidence that increases with age parallel to that of cardiovascular disease. Thus, we presupposed that hormone treatment, depending on its level of interference and lipoprotein changes, might influence the risk of atherosclerotic cardiovascular disease (3-5).
The effect of steroid hormones on lipoprotein metabolism described in extensive studies on oral contraceptives and oestrogen replacement therapy in postmenopausal women are well known (6) , but have scarcely been studied in men, bearing in mind the differences in plasma lipoprotein patterns between men and women. Orchidectomy was the first mode of androgen deprivation (1) and luliberin analogues have recently been introduced in the treatment of prostatic carcinoma (7, 8) . Several authors have described their effects on plasma lipoprotein profiles in men with advanced prostatic carcinoma, but most of these studies were incomplete and not randomized (5, (9) (10) (11) (12) .
Although lipoprotein metabolism in rats can not be extrapolated to humans, the aim of the present study was to investigate the effects of orchidectomy, oestrogen administration and luliberin analogue therapy on lipoprotein profiles in rats. To our knowledge, experimental studies on plasma lipoprotein profiles following androgen deprivation in Sprague-Dawley rats have not been previously reported.
Materials and Methods

Animals
Four groups of 20 male Sprague-Dawley rats (Oncins France Strain A-OFA rat-Prolabor Laboratories, Barcelona, Spain) aged from 6-8 weeks with a body weight of 200-275 g. were studied.
Control group
Twenty rats were kept in metabolic cages with an homogeneous and regular diet of standard Pecoris rat chow (Prolabor Laboratories) and water ad libitum for eight weeks. They were then fasted for eight hours, weighed and anaesthetized with ketamine 250 mg (2.5 ml) + diacepam 20 mg (4ml) + atropine 1 mg (1 ml) at a dose of 0.5 ml/100 mg of weight (i.m.)-Middle laparotomy was performed, a catheter inserted in the aorta artery and all its blood drawn for testosterone and lipoprotein analysis.
Lipoprotein analysis was performed by processing blood samples by centrifugation at 3000 min" 1 for 10 min. ) were isolated by density gradient ultracentrifugation in a TST 41.14 rotor. Serum cholesterol, serum triacylglycerols, cholesterol and triacylglycerols of lipoprotein fractions were measured enzymatically using a selective multichannel analyzer Eris (Eppendorf, Hamburg, Germany) and standardized with control sera (Qualitrol, Merck, Frankfurt, Germany). Proteins of each isolated fraction were determined by a colorimetric method.
Orchidectomy group
Twenty rats were kept in metabolic cages with an homogeneous and regular diet of standard Pecoris rat chow (Prolabor Laboratories) and water ad libitum for one week to become adapted. They were then weighed, and anaesthetized following the protocol described above, and bilateral orchidectomy was performed. The rats were kept in metabolic cages in the same conditions for a further seven weeks, being weighed, fasted for eight hours and blood samples obtained as before for testosterone (in all samples at levels of castration < 0.2 μg/l) and lipoprotein analysis.
Oestrogens group
Twenty rats were kept in metabolic cages with an homogeneous and regular diet of standard Pecoris rat chow (Prolabor Laboratories) and water ad libitum for one week to become adapted. They were then injected subcutaneously with fosfestrol (stilboestrol diphosphate, Honvan®) 3 mg/kg daily for five weeks, being weighed, fasted for eight hours and blood samples obtained as before for testosterone (in all samples at levels of castration < 0.2 μβ /1) and lipoprotein analysis. Fosfestrol was chosen for this study because of its use m clinical practice at our Department.
Luliberin analogue group
Twenty rats were kept in metabolic cages with an homogeneous and regular diet of standard Pecoris rat chow (Prolabor Laboratories) and water ad libitum for one week to become adapted They were then injected subcutaneously with triptoreline (Decapeptyl®) 300 pgfcg every 28 days for eight weeks (two doses), being weighed, fasted for eight hours and blood samples obtained as be fore for testosterone (in all samples at levels of castration < 0 2 μg/l) and lipoprotein analysis. Triptoreline was chosen for this study because of its use in clinical practice at our Department.
Statistical analysis
Normal distribution of continuous variables was confirmed by the Kolmogorov-Smirnoff test. Inter-group comparison was made by analysis of variance used factorially, and intra-group differences were tested by the Fisher PLSD test.
Results
Serum cholesterol and triacylglycerols and cholesterol, triacylglycerols and proteins in VLDL, IDL, LDL and HDL are shown in table 1. Significant differences were observed in serum cholesterol (p < 0.0001), for which the oestrogen group showed a statistically significant decrease compared with the other groups (p < 0.05). Likewise, the luliberin analogue group showed an increase in serum cholesterol versus the control group (p < 0.05). Significant differences were observed in VLDL-cholesterol (p < 0.042), with a fall in the oestrogen group compared with the control group (p < 0.05). Significant differences were also found in IDL-cholest erol (p < 0.0001), with increases in all three treatment groups versus the control group (p < 0.05). IDL-proteins showed significant differences (p < 0.0128), with increases in the orchidectomy group versus the control and oestrogen groups (p < 0.05). LDL-cholesterol showed significant differences (p < 0.0038), with increases in the luliberin analogue group versus the control and oestrogen groups (p < 0.05), and the orchidectomy group versus the oestrogen group (p < 0.05). Significant differences were also observed in LDL-proteins (p < 0.001), with increases in the orchidectomy and luliberin analogue groups compared with the control and oestrogen groups (p < 0.05). HDL-cholesterol showed significant differences (p < 0.0001), with a large fall in the oestrogen group versus all the other groups (p < 0.05). HDL-proteins showed significant differences (p < 0.0001), with a large increase in the oestrogen group versus the other three groups (p < 0.05), and increases in the orchidectomy group versus the control group (p < 0.05).
Discussion
Serum lipoprotein composition in rats differs significantly according to the rat strain. Furthermore, the finding of great variations in lipoprotein composition m animals of the same strain is noteworthy. These discrepancies are difficult to explain solely on the basis of nutritional status, and are probably related to pooling of small blood samples from several animals (13) (14) (15) (16) protein analysis was performed in each rat. Previous data do not permit comment on any association between lipoprotein profile and sex. On the contrary, age is a major factor in determining circulating lipoprotein levels (17) .
Serum lipoprotein composition and laboratory methods in male Sprägüe-Dawiey rats have been thoroughly reported (13, 16, 19, (21) (22) (23) (24) (25) (26) (27) (15) and Holtzman (20) .
In animals, the largest amount of cholesterol is carried by HDL (15) as we found in the Sprague-Dawiey strain (50%). Also, we observed that total serum cholesterol is much lower than in humans, as well as LDL-cholesterol, which suggests that rats are probably not a good model for studying atherogenic risk. This statement is confirmed by the atherogenic ratio (serum cholesterol/HDLcholesterol or LDL-cholesterol/HDL-cholesterol), which reflects the risk of cardiovascular disease (28, 29) . In the present study serum cholesterol/HDL-cholesterol ratio was 1.93 ± 0.40, and LDL-cholesterol/HDL-cholesterol ratio was 0.41 ± 0.18. Since a serum cholesterol/ HDL-cholesterol ratio of 3.5 or less is considered optimal in humans and an indicator of low cardiovascular risk (30) , it may in part explain why rats rarely suffer from atherosclerosis.
Orchidectomy has scarcely been studied in relation to lipoprotein profile in men with advanced prostatic carcinoma. Increases in serum cholesterol (5, 11, 12) , LDLapolipoprotein B (11) and serum and LDL-triacylglycerols (12) have been described. In rats, we observed an increase in IDL-cholesterol, IDL-proteins, HDL-proteins and LDL-proteins. In general, no great variations were noted compared with the control group. Perhaps the increase in LDL-apolipoprotein B may be consistent with a rise in the number of LDL particles, since each LDL particle contains only one apolipoprotein B. molecule (31) , which leads to increased cardiovascular risk.
The influence of oestrogens on lipoprotein profiles has been widely studied and shows differences between the effects of endogenous and exogenous gonadal hormones, between men and pre and postmenopausal women, and depending on the composition and dosage of the hormone administered (6) . Synthetic and conjugated oestrogens increase plasma VLDL and total triacylglycerols by enhancing their hepatic synthesis, particularly large VLDL particles which are directly catabolized by the liver rather than delipidated to small VLDL and LDL, and their elevation may thus be less atherogenic than other triacylglycerol-rich lipoproteins. A further main effect of oestrogens is to decrease LDL-cholesterol levels by increasing their clearance rate (increasing liver LDL receptors activity). Finally, the third most important effect of oestrogens is to raise HDL and HDL2-cholesterol and apolipoprotein A-I levels by inhibiting hepatic lipase activity (32) (33) (34) (35) (36) . In the present study, decreases in serum cholesterol, VLDL-cholesterol, LDL-cholesterol (although without statistical significance) and HDL-cholesterol, together with increases in IDL-cholesterol and HDL-proteins have been observed in oestrogen treated rats compared with those of the control group.
Although no benefits were observed in the first large study of oestrogens and cardiovascular risk (37) with oestrogen therapy, the majority of other large studies conclude that oestrogen administration is associated with a reduced incidence of coronary heart disease and cardiovascular mortality (38) (39) (40) , A similar lipoprotein profile is found in men with prostatic carcinoma following oestrogen therapy (5, 11, 12, 41 Finally, the increase in IDL-cholesterol observed in v ajl treatment groups compared with control group was remarkable, since recent studies point to the atherogenic properties of IDL particles in humans, instead of triacylglycerol-rich particles (36) .
